Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Gene Ther. 2012 Jun;19(6):367-73. doi: 10.1038/cgt.2012.22. Epub 2012 May 4.

Nanovector delivery of siRNA for cancer therapy.

Author information

1
The Methodist Hospital Research Institute, Houston, TX, USA.

Abstract

RNA interference holds the promise to knock down expression of every cancer gene. Both academic laboratories and pharmaceutical companies have committed heavily on manpower and financial resources to develop small interfering RNA (siRNA) cancer therapeutics over the last decade. Although significant advances have been made in the design of siRNA therapeutics and mechanism of action on cancer cell killing, there are still many hurdles to overcome including effective delivery of therapeutics in vivo. Nanotechnology has had an important role in the development of delivery vectors so far. This article summarizes current nanovectors for siRNA delivery, discusses technical challenges in overcoming biological barriers, and introduces the multistage vector system for tumor-specific delivery.

PMID:
22555511
PMCID:
PMC3842228
DOI:
10.1038/cgt.2012.22
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center